Abstract

A maladaptive inflammatory response has been implicated in the pathogenesis of severe COVID-19. This study aimed to characterize the temporal dynamics of this response and investigate whether severe disease is associated with distinct gene expression patterns. We performed microarray analysis of serial whole blood RNA samples from 17 patients with severe COVID-19, 15 patients with moderate disease and 11 healthy controls. All study subjects were unvaccinated. We assessed whole blood gene expression patterns by differential gene expression analysis, gene set enrichment, two clustering methods and estimated relative leukocyte abundance using CIBERSORT. Neutrophils, platelets, cytokine signaling, and the coagulation system were activated in COVID-19, and this broad immune activation was more pronounced in severe vs. moderate disease. We observed two different trajectories of neutrophil-associated genes, indicating the emergence of a more immature neutrophil phenotype over time. Interferon-associated genes were strongly enriched in early COVID-19 before falling markedly, with modest severity-associated differences in trajectory. In conclusion, COVID-19 necessitating hospitalization is associated with a broad inflammatory response, which is more pronounced in severe disease. Our data suggest a progressively more immature circulating neutrophil phenotype over time. Interferon signaling is enriched in COVID-19 but does not seem to drive severe disease.

Details

Title
Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19
Author
Prebensen, Christian 1 ; Lefol, Yohan 2 ; Myhre, Peder L. 3 ; Lüders, Torben 4 ; Jonassen, Christine 5 ; Blomfeldt, Anita 6 ; Omland, Torbjørn 3 ; Nilsen, Hilde 2 ; Berdal, Jan-Erik 7 

 Oslo University Hospital, Department of Infectious Diseases, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); University of Oslo, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921) 
 University of Oslo, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); University of Oslo, Department of Microbiology, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921) 
 University of Oslo, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Akershus University Hospital, Department of Cardiology, Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X) 
 University of Oslo, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Akershus University Hospital, Department of Clinical Molecular Biology, Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X) 
 Østfold Hospital Trust, Center for Laboratory Medicine, Grålum, Norway (GRID:grid.412938.5) (ISNI:0000 0004 0627 3923) 
 Akershus University Hospital, Department of Microbiology and Infection Control, Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X) 
 University of Oslo, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Akershus University Hospital, Department of Infectious Diseases, Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X) 
Pages
10368
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2829617272
Copyright
© The Author(s) 2023. corrected publication 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.